NASDAQ:RELVReliv International Stock Price, Forecast & News

Reliv International's stock was trading at $3.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RELV stock has increased by 13.2% and is now trading at $3.6783. View which stocks have been most impacted by Coronavirus.

Reliv International is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Reliv International.

Reliv International, Inc (NASDAQ:RELV) released its quarterly earnings results on Friday, May, 15th. The company reported $0.38 EPS for the quarter. The business earned $10.28 million during the quarter. Reliv International had a negative net margin of 1.13% and a negative return on equity of 3.52%. View Reliv International's earnings history.

Headlines about RELV stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Reliv International earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news about Reliv International.

Reliv International saw a increase in short interest in June. As of June 15th, there was short interest totaling 5,300 shares, an increase of 5,200.0% from the May 31st total of 100 shares. Based on an average daily volume of 12,700 shares, the short-interest ratio is currently 0.4 days. Currently, 0.5% of the company's stock are short sold. View Reliv International's Current Options Chain.

Some companies that are related to Reliv International include PDS Biotechnology (PDSB), AzurRx BioPharma (AZRX), Kazia Therapeutics (KZIA), Spring Bank Pharmaceuticals (SBPH), OHR Pharmaceutical (OHRP), Cyclerion Therapeutics (FBRX), IntelGenx Technologies (IGXT), Cyclacel Pharmaceuticals (CYCC), Eyegate Pharmaceuticals (EYEG), OTCMKTS:EMBI (EMBI), Iterum Therapeutics (ITRM), Nemus Bioscience (NMUS), Salarius Pharmaceuticals (SLRX), Intec Pharma (NTEC) and Uluru (ULUR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Reliv International investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Gold Standard Ventures (GSV), Gold Standard Ventures (GSV), Primo Water (PRMW), Rite Aid (RAD), RadNet (RDNT), Ring Energy (REI), Ring Energy (REI) and VIVUS (VVUS).

Reliv International trades on the NASDAQ under the ticker symbol "RELV."

Shares of RELV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RELV stock can currently be purchased for approximately $3.68.

Reliv International has a market capitalization of $6.44 million and generates $35.06 million in revenue each year. Reliv International employs 156 workers across the globe.

The official website for Reliv International is www.reliv.com.

Reliv International's mailing address is 136 CHESTERFIELD INDUSTRIAL BLVD, CHESTERFIELD MO, 63006. The company can be reached via phone at 636-537-9715 or via email at [email protected]